Latest "Criticality Experiments Enhance Nuclear Safety Security Effectiveness" News Stories - Page: 4

06:38 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Criticality Experiments Enhance Nuclear Safety Security Effectiveness" found in our extensive news archives from over 250 global news sources.

More Information about Criticality Experiments Enhance Nuclear Safety Security Effectiveness on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Criticality Experiments Enhance Nuclear Safety Security Effectiveness for you to read. Along with our medical data and news we also list Criticality Experiments Enhance Nuclear Safety Security Effectiveness Clinical Trials, which are updated daily. BioPortfolio also has a large database of Criticality Experiments Enhance Nuclear Safety Security Effectiveness Companies for you to search.

Showing "Criticality Experiments Enhance Nuclear Safety Security Effectiveness" News Articles 76–100 of 8,900+

Friday 22nd March 2019

Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy

Source: Streetwise Reports   03/23/2019 A ROTH Capital Partners report reviewed this New Jersey firm's plans for its lead asset.In a March 21 research note, ROTH Capital Partners analyst Jerry Isaacson reported that Matinas BioPharma Holdings Inc. (MTNB:OTC.MKTS) is "positioned for success" following its equity raise, "executed under favorable terms." Expected gross pr...

FitLife Brands Announces 2018 Results

FitLife Brands, Inc. (“FitLife”) (OTC Pink: FTLF), an international provider of innovative and proprietary nutritional supplements for health-conscious consumers marketed under the brand names NDS Nutrition Products™ ("NDS") (, PMD® (, SirenLabs® (

Gossamer Bio Announces 2018 Annual Financial Results

Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the year ended December 31, 2018 and provided an update on recent corporate developments. ...

Teva Announces Launch of a Generic Version of EXJADE® (deferasirox) Tablets For Oral Suspension in the United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of EXJADE®1 (deferasirox) Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, in the U.S. Deferasirox Tablets for Oral Suspension are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in ...

FDA: Higher Risk for Death Found With Venclexta in Multiple Myeloma

FRIDAY, March 22, 2019 -- A safety statement was issued yesterday by the U.S. Food and Drug Administration regarding risks found to be associated with the investigational use of Venclexta (venetoclax) for treatment of patients with multiple...

Two Brothers Pork Skins Recalls Pork Skin Products Due to Misbranding and Failure to Produce Under A HACCP Plan

Two Brothers Pork Skins, a Kannapolis, N.C. establishment, is recalling an undetermined amount of pork skin products because the products were produced without meeting the federal requirements to develop and implement a hazard analysis and system of preventive controls to improve the safety of the products, known as Hazard Analysis and Critical Control Points; the omission of safe handling instruc...

FDA Warns of Cyber Risk in Medtronic ICD, CRT-D Telemetry Systems

Hackers could potentially exploit security vulnerabilities in certain Medtronic CareLink systems to reprogram implanted devices, if they are nearby with the right equipment, says the agency. News Alerts

Magnetic Stir Bars Carry 'Memory' From Previous Flasks, Tubes

NewsHigh level of surface contaminations of magnetic stir bars brings highly reactive traces of metal species from previous experiments to the next ones.

Women’s Voices Says Clock Hasn’t Run Down On Parabens Safety; Did CIR Call The Game Early?

Recent statements from Cosmetic Ingredient Review leadership and Expert Panel members affirming the safety of parabens, while their latest review...   

SoFi and Delos Partner to Bring Delos’ Home Wellness Solutions to Homeowners

The partnership will help drive accessibility of Delos’ health and wellness technology to homes across the U.S. Wellness real estate and technology company, Delos™, is collaborating with online personal finance company, SoFi, to ensure homeowners will have an accessible financing path to implement Delos’ DARWIN Home Wellness Intelligence Network,...

Health And Wellness Weekly Trademark Review March 5-19, 2019

Trademarks registered and published for opposition with USPTO in Class 3 – cosmetics and cleaning Preps, and Class 5 –pharmaceuticals...   

The Dark Side Of Artificial Intelligence: Increased Efficiency Comes With Ominous Threat Of Vulnerability To Hackers

A report warns that artificial intelligence can be easily duped with tiny pieces of data. The authors say bad actors could hack into records and make it seem like there's an illness there that isn't. But more likely is that doctors, hospitals and other organizations could manipulate the A.I. in billing or insurance software in an effort to maximize the money coming their way. In other health techn...

First Reputation-based Blockchain Guarantees Security Against 51 Percent Attacks

NewsResearchers propose a blockchain system to guarantee proper performance even with over 51% of a system's power compromised.

Medtronic addressing cybersecurity vulnerabilities in cardiac devices

The Department of Homeland Security has issued an alert on two cybersecurity vulnerabilities found in Medtronic's standard im -More- 

Senseonics Launches the Eversense® Bridge Patient Access Program in the U.S.

Patients Can Access Long-term Eversense CGM for only $99* Under Program Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, has announced the launch of the Eversense Bridge Program. ...

Biogen and Eisai terminate trial of Alzheimer’s drug on efficacy grounds

Biogen and Eisai have announced they are discontinuing two Phase III trials, Engage and Emerge, evaluating the safety and efficacy...Read More... The post Biogen and Eisai terminate trial of Alzheimer’s drug on efficacy grounds appeared first on Pharmaceutical Technology.

Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer

INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer Ovarian cancer is the fifth leading cause of cancer death among women Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor ...

Specialists petition FDA over opioid approval process

FDA officials have called on the federal agency to halt the approval of new narcotic painkillers. Dr Sidney Wolfe, a former member of the FDA’s drug safety committee, and Dr Raeford Brown, the present chair of the agency’s opioid advisory committee, have launched a formal process to prevent the FDA from approving new opioids. The doctors claim the FDA has failed to acknowledge the ongoing opio...

Experiments with Roundworms Suggest Alternatives for the Treatment of Schizophrenia

NewsSchizophrenia is a highly complex mental disorder with unknown causes and no cure. Contributed Author: 

Vizient to Participate in Becker’s Hospital Review’s Webinar on Pharmacy Trends

Vizient announces its participation in the panel discussion for the upcoming webinar, “What’s Trending in Hospital Pharmacy in 2019,” hosted by Becker’s Hospital Review. The webinar is scheduled from noon to 1 p.m. CDT Wednesday, Marc

$1 Billion for Mental Health: The Reality of de Blasio’s ‘Revolutionary’ Plan

It has been difficult to gauge the effectiveness of ThriveNYC, an expensive and sprawling mental health initiative.

Atezolizumab Safe in Advanced Urothelial Cancer

The SAUL phase 3b trial met its primary safety endpoint, but the comparative efficacy of the anti-PD-L1 agent in a broader population is still up in the air. Medscape Medical News

The PepsiCo Foundation Expands Access to Safe Water for More Than 22 Million People Worldwide; Part of PepsiCo's Broader Aim to Contribute to Positive Water Impact

SOURCE: PepsiCo DESCRIPTION:PURCHASE, N.Y., March 22, 2019 /3BL Media/ - PepsiCo announced today that it has helped more than 22 million people in underserved communities around the world gain access to safe water since 2006. In the last year alone, PepsiCo and its partners expanded access for more than 6 million people, indicating the company is on track to exceed its goal to support a total o...

Novartis plans for Alcon spin-off on April 9, 2019

Novartis International AG / Novartis plans for Alcon spin-off on April 9, 2019 . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exch...

Valley Med Flight Earns Successive NAAMTA Accreditation

Through the accreditation process, Valley Med Flight demonstrated compliance in each of the defined standards, excelled in identifying best practice procedures, and instilled these values in each employee. NAAMTA verified their compliance through employee interviews, on-site evaluations, and process reviews, all of which were conducted using ISO 9001:2015 auditing guidelines. GRAND FORKS, N.D. (PR...

Quick Search


News Quicklinks